Youssef Rddad

2 weeks ago | oncologynewscentral.com | Youssef Rddad

Patients with Bacillus Calmette-Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer (NMIBC) demonstrated durable responses after treatment with a novel, intravesical drug delivery system. The results were based on findings from the ongoing phase 2b SunRISe-1 trial, which were presented at the 2025 American Urological Association Annual Meeting in Las Vegas and published in The Journal of Urology.

2 weeks ago | oncologynewscentral.com | Youssef Rddad

On April 23, the U.S. Food and Drug Administration (FDA) approved first-line penpulimab-kcqx (Akeso) in combination with cisplatin or carboplatin and gemcitabine for adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). The agency also approved penpulimab as monotherapy for adults with metastatic non-keratinizing NPC who received at least one line of treatment and had disease progression while on or after platinum-based chemotherapy.

3 weeks ago | oncologynewscentral.com | Youssef Rddad

Bispecific antibodies have reshaped treatment approaches in relapsed multiple myeloma, but delivering them in a community setting comes with logistical and clinical hurdles. Ira Zackon, MD, of New York Oncology Hematology in Albany, discusses how his team in Upstate New York built the infrastructure to safely administer bispecifics, from dedicated clinical teams to hospital partnerships.

3 weeks ago | oncologynewscentral.com | Youssef Rddad

Enfortumab vedotin (EV) plus pembrolizumab (EV+P) has quickly moved to the forefront of treatment for advanced urothelial carcinoma. This has raised questions about sequencing, resistance, and next lines of treatment. In an interview with Oncology News Central, Parminder Singh, MD, of the Mayo Clinic in Phoenix, outlined approaches to frontline decision-making and shared insights on options after disease progression.

3 weeks ago | oncologynewscentral.com | Youssef Rddad

Switch maintenance with paclitaxel and ramucirumab extended progression-free survival (PFS) compared with continued first-line chemotherapy in patients with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer, according to final results of a phase 3 study. However, the lack of overall survival (OS) benefit and the trial’s design raise questions about whether the findings will affect practice, an expert said.